Connect
MJA
MJA

Weight gain and diabetes with “second-generation” antipsychotic drugs

Andrew Firestone
Med J Aust 2005; 182 (12): . || doi: 10.5694/j.1326-5377.2005.tb06860.x
Published online: 20 June 2005

Andrew Firestone


  • Monash University, Clayton, VIC 3168.


Correspondence: afire@tpg.com.au

  • 1. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596-601.
  • 2. Graham KA, Perkins DO, Edwards LJ, et al. Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. Am J Psychiatry 2005; 162: 118-123.
  • 3. Holzer L, Paiva G, Halfon O. Quetiapine-induced weight gain and escitalopram. Am J Psychiatry 2005; 162: 201-202.
  • 4. Lambert TJR, Chapman LH, on behalf of the Consensus Working Group. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement. Med J Aust 2004; 181: 544-548. <MJA full text>
  • 5. Firestone A. Diabetes, psychotic disorders and antipsychotic therapy: a consensus statement [letter]. Med J Aust 2004; 182: 310. <MJA full text>

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.